Article

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.

National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892, USA.
New England Journal of Medicine (Impact Factor: 54.42). 07/2009; 360(23):2426-37. DOI: 10.1056/NEJMoa0807865
Source: PubMed

ABSTRACT Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone.
We studied nine children from six families who had neonatal onset of sterile multifocal osteomyelitis, periostitis, and pustulosis. Response to empirical treatment with the recombinant interleukin-1-receptor antagonist anakinra in the first patient prompted us to test for the presence of mutations and changes in proteins and their function in interleukin-1-pathway genes including IL1RN.
We identified homozygous mutations of IL1RN in nine affected children, from one family from Newfoundland, Canada, three families from The Netherlands, and one consanguineous family from Lebanon. A nonconsanguineous patient from Puerto Rico was homozygous for a genomic deletion that includes IL1RN and five other interleukin-1-family members. At least three of the mutations are founder mutations; heterozygous carriers were asymptomatic, with no cytokine abnormalities in vitro. The IL1RN mutations resulted in a truncated protein that is not secreted, thereby rendering cells hyperresponsive to interleukin-1beta stimulation. Patients treated with anakinra responded rapidly.
We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote this autosomal recessive autoinflammatory disease caused by mutations affecting IL1RN. The absence of interleukin-1-receptor antagonist allows unopposed action of interleukin-1, resulting in life-threatening systemic inflammation with skin and bone involvement. (ClinicalTrials.gov number, NCT00059748.)

Full-text

Available from: Chyi-Chia Richard Lee, Jun 16, 2015
1 Follower
 · 
528 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interleukins have become well known regulators of innate and adaptive immunity-related tissue inflammation. Recently, IL-22 has gained a lot of interest for its unique functions in maintaining and regaining epithelial integrity. IL-22 is exclusively secreted by different immune cell subsets, while IL-22 receptors are mainly expressed by epithelial cells. As the kidney is largely an epithelial organ the functional role of IL-22 in the kidney deserves to be explored in detail. Here we briefly summarize the key features of IL-22 biology and review the available data on its expression and functional roles in kidney injury and kidney regeneration. Furthermore, we provide suggestions how to explore this evolving field in the future. Copyright © 2015, American Journal of Physiology - Renal Physiology.
    American journal of physiology. Renal physiology 03/2015; 308(10):ajprenal.00005.2015. DOI:10.1152/ajprenal.00005.2015 · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE OF THE REVIEW: Inherited autoinflammatory syndromes are conditions caused by mutations of proteins playing a pivotal role in the regulation of the innate immunity leading to an uncontrolled inflammation. The understanding of the molecular pathways involved in these disorders has shed a new light on the pattern of activation and maintenance of the inflammatory response and disclosed new molecular therapeutic targets. In this review we give a start of the art of the use of biologics in these disorders. MAIN TOPICS: The dramatic response to anti IL-1 drugs in cryopyrin-associated periodic syndromes represents the brightest example of the possibility to completely dampen inflammation in these severe disorders with the selective blockade of a single pivotal cytokine. Periodic fevers are characterized by recurrent episodes of fever, usually treated with on demand steroids. However the increasing frequency of fever episodes or the development of a chronic disease course may require a continuous long-term treatment, with anti-TNF or IL-1 blockers in mevalonate kinase deficiency and TNF-receptor associated periodic syndrome. Anti-IL-1 treatment is also effective in FMF patients resistant or partially responsive to colchicine. The deficiency of the interleukin-1-receptor antagonist (DIRA) is caused by mutations in the gene encoding for the interleukin-1 receptor antagonist (IL-1Ra). In this case t he recombinant IL-1Ra (anakinra) is the treatment of choice. Due to their extreme rarity the response to the available biologic drugs in other autoinflammatory diseases is still largely anecdotal.
    Autoimmunity reviews 08/2012; 12(1):81-6. DOI:10.1016/j.autrev.2012.07.027 · 7.10 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Candida albicans is an opportunistic fungal pathogen that induces strong proinflammatory responses, such as IL-1b production. Much less is known about the induction of immune modulatory cytokines, such as the IL-1 receptor antagonist (IL-1Ra) that is the main natural antagonist of IL-1, by C. albicans. Methods: Peripheral blood mononuclear cells (PBMC) of healthy individuals were stimulated with C. albicans and different components of the fungal cell wall. The role of pathogen recognition receptors (PRRs) for the induction of IL-1b and IL-1Ra was investigated by using specific blockers or in PBMC from Dectin-1 deficient patients. Results: C. albicans induced a strong IL-1Ra response, and this induction was primarily induced by the cell-wall component b-glucan. Blocking IL-1Ra significantly increased C. albicans b-glucan hyphae induced IL-1b and IL-6 production. Surprisingly, blocking the b-glucan receptor Dectin-1 or the downstream Syk or Raf-1 pathways only marginally reduced C. albicans-induced IL-1Ra production, while blocking of the complement receptor 3 (CR3), TLR2 or TLR4 had no effect. In line with this, blocking MAP kinases had little effect on Candida-induced IL-1Ra production. PBMC isolated from Dectin-1 deficient patients produced normal IL-1Ra amounts in response to C. albicans stimulation. Interestingly, the IL-1Ra synthesis induced by b-glucan was blocked by inhibitors of the Akt/PI3 K pathway. Conclusions: b-glucan of C. albicans induces a strong IL-1Ra response, which is independent of the b-glucan receptors dectin-1 and CR3. These data strongly argue for the existence of an unknown b-glucan receptor that specifically induces an Akt/PI3 K-dependent anti-inflammatory IL-1Ra response upon recognition of C. albicans.
    Cytokine 02/2015; 71(2):215-222. DOI:10.1016/j.cyto.2014.10.013 · 2.87 Impact Factor